#181: What's going to be hot at ACC 2013; rivaroxaban STEMI study hits print as FDA delivers setback; Watchman ups quality of life vs chronic warfarin in nonvalvular AF; FDA again seeks more info on rivaroxaban in ACS

What's going to be hot at ACC 2013; rivaroxaban STEMI study hits print as FDA delivers setback; Watchman ups quality of life vs chronic warfarin in nonvalvular AF; FDA again seeks more info on rivaroxaban in ACS

Source: Radio TheHeart.org - March 7, 2013 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts